MASP inhibitory compounds and uses thereof

US11667675B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Donald Bierer · Daly City, US
• Ingo Flamme · Bergneustadt, DE
• Dmitry Zubov · Remscheid, DE
• Thomas Neubauer · Wuppertal, DE
• Adrian Tersteegen · Wuppertal, DE
• Cathleen Juhl · Hamburg, DE
• Marie Glatz · Wuppertal, DE
• Jan DREHER · Wuppertal, DE
• Simon Holton · Berlin, DE
• Carsten TERJUNG · Bochum, DE
• Lars Baumann · Vancouver, CA
• Thorsten Poethko · Schwelm, DE
• Jiancheng Xiong · 红钢城街道, CN
• Yibo Qiu · Ann Arbor, US

Key dates

• Filing date: Dec 30, 2020
• Grant date: Jun 6, 2023
• Expiry date: Dec 30, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.